Tumours with BRCA1 or BRCA2 mutations had increased immune infiltrates compared with high‐grade serous without mutations.28 Strickland et al29 reported immunohistochemistry studies demonstrating that BRCA1/2‐mutated tumours exhibited significantly increased CD3+ and CD8+ tumour‐infiltrating lymphocytes (TILs) compared to HR proficient (tumours without alterations in HR genes) tumours. The gene discussed is BRCA1; the disease is neoplasm.